Amivantamab (EGFR×MET), a KIH-based BsAb, has shown efficacy in non-small-cell lung cancer (NSCLC) with EGFR mutations and MET amplification by inhibiting both pathways. This evidence concerns the gene EGFR and non-small cell lung carcinoma.